Challenge Bioproducts Co., Ltd. is a manufacturer of biochemical products since 1990, located in Touliu Industrial Park in the middle of Taiwan. The company has been committed to making researches and development on bioproducts for biomedical, animal feed and agricultural applications.
All of the CBC bioproducts are particularly designed for solving environmental pollution problems & up-grading farming produce.
CBC Plant in Touliu Industrial Park, Taiwan
- To work for people to enjoy a natural and healthy life in the world
- To help create an ever-growing agriculture and preserve an unpolluted environment for the world
CBC's Ecosystem Pond
Our products are sold all over the world, from Asia, Europe,
North, South America, and more.
- Challenge Bioproducts Co., Ltd. began in Touliu.
- The first factory was built in Touliu Industrial Park.
- Office and R&D laboratory built in Taichung.
- CBC's new factory and laboratory built in Touliu.
- CBC was awarded a R.O.C. (Taiwan) patent on the production technology of Genipin.
- In order to help more 3rd degree patients in the world, CBC signed Supply Agreement and Technology Transfer agreements with Mediwound Ltd. for the pineapple enzyme mixture Bromelain SP.
- CBC was awarded an USA patent on the application of Genipin on the biomedical engineering field.
- CBC was awarded an European patent on the application of Genipin on the biomedical engineering field.
- CBC was awarded a Taiwan patent on the application of Genipin on the biomedical engineering field.
- CBC was awarded a P.R.C. (Mainland China) patent on the application of Genipin on the biomedical engineering field.
- Chappion Biotechnology Co., Ltd. was established to focus on the R&D and production of high-tech biomedical and health food ingredients.
- President CK Lin was awarded the 5th outstanding alumni of the Engineering School of National Tsing-Hua University of Taiwan.
- CBC was awarded a Canadian patent on the application of Genipin on the biomedical engineering field.
- CBC was awarded a Taiwan patent on the application of Genipin on oil body.
- The first plant of Chappion Biotechnology Co., Ltd. was established in Touliu Industrial Park, Taiwan.
- Challenge Bioproducts Co., Ltd. and Chappion Biotechnology Co., Ltd. were both awarded ISO 22000 and HACCP certification, by Swiss Certification.
- MediWound Ltd. (Israel) achieved promising Phase III trial results on its 3rd degree burn treatment product in the EU, while the US FDA Phase III trials are underway. CBC, as the sole supplier of Bromelain SP, expects the project to revolutionize treatments for 3rd degree burn patients.
- Manufacturing facilities and hardwares for the production of API intermediate (Bromelain SP) were upgraded, along with an upgraded quality system suitable for Bromelain SP.
- Renewal of ISO 22000 and HACCP certification by UKAS (United Kingdom Accreditation Service) via SGS.
- Challenge Bioproducts & Chappion Biotechnology facilities were audited by Teva Pharmaceuticals Europe (Global Compliance Group), and obtained EU GMP suitability declaration as a manufacturer of API intermediate (Bromelain SP).
- Debrase(Nexobrid) receives marketing approval in Europe by EMA, and becomes "the first medical treatment for removal of eschar from severe burn wounds". It is also the first plant-derived enzymatic drug for eschar removal for burn patients.
- President CK Lin was invited to the Taiwan-Israel Biotechnology Forum with two Israeli Nobel Laureates at NTHU, Taiwan.
- To this date, CBC Genipin has been used by more than 220 research institutes/universities in over 45 countries in the world, and published more than 340 peer-reviewed scientific research literatures. We look forward to the bright future of Genipin as an API.
- Israel’s Mediwound Ltd. (formerly a subsidiary of TEVA, the world’s largest generic drug manufacturer) was listed on NASDAQ in the United States.
- The U.S. Biomedical Advanced Research and Development Authority (BARDA) signed an agreement with Mediwound Ltd., designating the new bromelain-based drug as an emergency procurement item for the U.S. FDA, and provided research and development grants (for diabetes/pressure ulcers).
- Create “ 挺自然™ (TeamNature™) ” brand.
- Collaboration with Swiss nutraceutical brand: innovative Taiwan-grown organic cucumber extract for health food (for athletes on sports recovery).
- Conducted the “Taiwan Pineapple Stem Collection – Bromelain Study ” with MediWound, Chiayi Agricultural Experiment Station and National Chung Hsing University.
- Signing of an MOU with Australian medical team on the anti-cancer enzyme project.
- CBC was awarded the Certification of Food Sanitation and Safety Management Systems by Taiwan FDA (manufacturing of natural flavor enhancer).
- CBC was awarded the Kosher Certification.
- Collaboration with Japanese nutraceutical brand: innovative Pumpkin Seed Extract for health food (improve sleeping quality).
- Co-hosted the 14th Asian Congress on Biotechnology (ACB 2019) in Taipei. By our invitation, Prof. Douglas Clark the member of the National Academy of Engineering, USA was the plenary speaker and biotech forum speaker.
- Received government grant and successfully completed the R&D project on Instant Tzen Oolong Tea (CITD), and presented the product with our collaborator National Chung Hsing University (Prof. Jason Tzen) in 2019 BIO Asia-Taiwan Conference and Exhibition.
- CBC upgraded to ISO22000:2018 & HACCP certifications by UKAS.
- Since 2015, US BARDA has funded more than 200 million USD for the bromelain project, which supports clinical trials, R&D, agricultural research, quality system improvement and emergency procurement.
- NexoBrid receives Taiwan FDA approval (distributed by Holy Stone Healthcare Co., Ltd.) for deep partial-thickness and full-thickness debridement for adults. The enzyme made from Taiwanese pineapple can finally be used on saving Taiwanese burn patients.
- After successful GMP inspections at CBC and MW, NexoBrid receives US FDA approval for the treatment of severe thermal burns in adults. It is also approved in Japan for people of all ages. This botanical drug is now approved in 44 countries.
- Co-hosted the 2022 AFOB Biotech Forum in Taiwan.
- Co-hosted the 28th BEST-YABEC International Joint Symposium.
- President CK Lin was awarded the BEST fellow medal.
- Chappion Biotech was awarded the 20th Taiwan Golden Root Award, which recognizes outstanding companies with a strong combination of local root and global impact.
- To this date, more than 1000 scientific publications have cited the use of CBC reagents/products, in more than 52 countries, which includes genipin, bromelain, tea extracts and more.
